Aviv Clinics Partners with Koterra to Expand Veteran Access to Lifesaving TBI and PTSD Treatment
World-renowned brain treatment center is teaming up with a Tampa-based nonprofit to bring hyperbaric oxygen therapy treatments for Veterans across...
Brain
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal...
PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"),...
Axxess Partners With Zing Performance to Expand Access to Brain Health Solutions Through Home-Based Care
DALLAS, June 30, 2025 /PRNewswire/ -- Axxess, the leading global technology platform for healthcare at home, has partnered with Zing...
Danone North America Invests in the Future of Microbiome Science with 2024-2025 Fellowship Awards
Two graduate students receive grants supporting their research into the gut microbiome and probiotics in a program championing the next...
MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY
In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput...
Rewriting the Timeline of Detection: Linus Health’s Digital Platform Uncovers the Earliest Signs of Cognitive Decline
New research reveals that subtle response-time biomarkers—captured in minutes via digital assessments—can flag Alzheimer's and dementia risk far earlier than...
Apollo Biowellness, Inc., f/k/a Resonate Blends, Inc., Corporate Update
North Bergen, New Jersey--(Newsfile Corp. - June 26, 2025) - Apollo Biowellness, Inc. formerly known as Resonate Blends, Inc. (OTC...
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE...
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated...
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in...
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Scott McGohan Launches Mental Health Engagement Catalyst One Morning with Vital Brand-Development Support from Hyperquake
DAYTON, Ohio and CINCINNATI, June 25, 2025 /PRNewswire/ -- Independent creative strategy, branding, and experience design agency Hyperquake today announced...
Corundum Convergence Institute and the University of Tokyo’s International Research Center for Neurointelligence Launch Inaugural Neuroscience Entrepreneurship Workshop
Neuro-inspired Computation and Entrepreneurship Workshop Will Equip the Next Generation of Neuroscience Entrepreneurs with Foundational Tools for Startup Creation TOKYO,...
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis...
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE...
ORYZON to Host Virtual KOL Event on July 9, 2025
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial...
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive...
DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain
The Award Highlights the Promise of Exclusively Targeting Peripheral Opioid Receptors to Treat Chronic Pain Without the Risk of Addiction...
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in...